8-K 1 d57846_8-k.txt CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2004 REPLIGEN CORPORATION (Exact name of registration as specified in charter) Delaware 0-14656 04-2729386 (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (781) 250-0111 -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Item 5. Other Events. On January 5, 2004, Repligen Corporation announced that its phase 3 study of secretin for autism failed to meet the study's dual primary endpoints and that development of secretin for schizophrenia would continue. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 7. Financial Statement and Exhibits. (c) Exhibit No. Exhibit ----------- ------- 99.1 Press Release, dated January 5, 2004 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Dated: January 5, 2004 By: /s/ Walter C. Herlihy --------------------------------- Walter C. Herlihy President and Chief Executive Officer EXHIBIT INDEX Exhibit No. Exhibit ----------- ------- 99.1 Press Release, dated January 5, 2004